Table 3.
Proportion of responding Member States reporting having HCV testing guidance (covering diagnostic tests, PWID, and referral to treatment/care) and the use of optimal therapies in first-line treatment for HCV.
| HCV Testing guidance which covers the following: |
Interferon-free direct-acting antiviral regimens considered the first line of treatment for the following: |
|||||
|---|---|---|---|---|---|---|
| HCV diagnostic test, n (% of N) | HCV testing of PWID, n (% of N) | Referral to treatment/care, n (% of N) | All patients, n (% of N) | For selected patients according to prioritization1, n (% of N) | No, n (% of N) | |
| Total responding Member States (N = 135) |
87 (64%) | 62 (46%) | 84 (62%) | 51 (38%) | 40 (30%) | 44 (33%) |
| By WHO region: | ||||||
| Eastern Mediterranean (16) | 15 (93%) | 10 (63%) | 12 (75%) | 9 (56%) | 3 (19%) | 4 (25%) |
| Western Pacific (19) | 12 (63%) | 8 (42%) | 11 (58%) | 7 (37%) | 2 (11%) | 10 (53%) |
| Americas (19) | 12 (63%) | 4 (21%) | 11 (58%) | 6 (32%) | 3 (16%) | 10 (53%) |
| South-East Asia (8) | 5 (75%) | 4 (50%) | 5 (63%) | 4 (50%) | 3 (38%) | 1 (13%) |
| European (46) | 33 (72%) | 33 (72%) | 38 (83%) | 18 (39%) | 22 (48%) | 6 (13%) |
| African (27) | 9 (33%) | 3(11%) | 7 (26%) | 7(26%) | 7 (26%) | 13 (48%) |
| By income classification: | ||||||
| High (41) | 30 (73%) | 28 (68%) | 33 (81%) | 17 (42%) | 21 (51%) | 3 (7%) |
| Upper-middle (32) | 26 (81%) | 13 (41%) | 24 (75%) | 10 (31%) | 9 (28%) | 13 (41%) |
| Lower-middle (35) | 19 (54%) | 15 (43%) | 19 (54%) | 16 (46%) | 4 (11%) | 15 (43%) |
| Low (24) | 10 (42%) | 3 (13%) | 5 (21%) | 7 (29%) | 5 (21%) | 12 (50%) |
| n.a. (3) | 2 (67%) | 3(100%) | 3 (100%) | 1 (33%) | 1 (33%) | 1 (33%) |
| Estimated number of people living with chronic HCV in millions (71) | 46 (64%) | 38 (53%) | 48 (68%) | 35 (49%) | 11 (16%) | 11 (16%) |
HCV, hepatitis C virus; PWID, people who inject drugs; WHO, World Health Organization.
1
e.g. restrictions on who receives treatment based on disease stage or risk group.